Happy Thursday Everyone!
We hope everyone’s spring is off to a good start! This week, we’re highlighting four articles about research updates. We have news pertaining to Methylmalonic Acidemia patients and families followed by an update on Hemophilia A treatment research. Next, we have news on a trial discontinuation as well as a Multiple Myeloma approval in England.
Sit back and enjoy this week’s Editor’s Choice.
[one_half]
[/one_half] [one_half_last]
NIH Works With Patients and Families on Methylmalonic Acidemia Research
The NIH is taking steps to involve the communities affected by this rare disease.
[/one_half_last] [one_half]
[/one_half] [one_half_last]
Preventive Use of Extended Half-Life Therapies Provides Enhanced Benefit for Hemophilia A Patients
Research shows this treatment could help Hemophilia A patients prevent bleeds before they happen.
[/one_half_last]
[one_half]
[/one_half] [one_half_last]
Phase III Ovarian Cancer Clinical Trial to be Discontinued
Ovarian cancer treatment development experiences a setback.
[/one_half_last] [one_half]
[/one_half] [one_half_last]
New Combination Therapy for Multiple Myeloma Approved in England
Our friends across the pond have new treatment options for Multiple Myeloma.
[one_half]
